To print or not to print, that is the question: how close are we to clinical translation of contemporary bioinks?

In this Editorial, the authors discuss what is currently being done and what is required for the adoption of clinical bioprinting. Despite the continual addition of names to organ transplant registers worldwide, and the many millions of individuals with tissue loss resulting in structural, cosmetic and functional problems, there is still no sustainable solution. One promising approach to alleviate these problems and revolutionize current medical treatments is biofabrication, which over the last decade has rapidly evolved from a niche research area into more mainstream, integrated bioprinting platforms. The success of this shift has been attributed to advances in engineering of...